European Companies Search Engine
UK funding (£579,056): Understanding and predicting aggregation in biopharmaceuticals Ukri1 Nov 2011 UK Research and Innovation, United Kingdom
Overview
Text
Understanding and predicting aggregation in biopharmaceuticals
| Abstract | Currently, one of the bottle necks to developing cheaper protein therapeutics is the cost of the downstream bioprocessing and formulation steps. A key problem is the loss of active protein therapeutic to irreversible aggregation throughout the bioprocess. Other problems can arise during chromatography or filtration when encountering high protein concentrations which could lead to high viscosites or even precipitation. The focus of this work is to develop predictive methods for identifying problematic conditions early on in the bioprocess. These could then be used for identifying changes to the protein to minimize the problems. Alternatively, the method could be used for optimizing the solvent properties (pH, buffer type and concentration) or finding other small molecule additives to be used in order to avoid aggregation or increase protein solubility. We benchmark our approach by studying antibodies and antibody fragments due to their growing importance as human therapeutics. |
| Category | Research Grant |
| Reference | BB/I017194/1 |
| Status | Closed |
| Funded period start | 01/11/2011 |
| Funded period end | 30/11/2014 |
| Funded value | £579,056.00 |
| Source | https://gtr.ukri.org/projects?ref=BB%2FI017194%2F1 |
Participating Organisations
| The University of Manchester | |
| EPSRC | |
| AstraZeneca | |
| Lund University | |
| University of Copenhagen | |
| Technical University of Denmark | |
| Wyatt Technology Corporation | |
| Novozymes | |
| Albumedix Ltd | |
| Ludwig Maximilian University of Munich (LMU Munich) |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: The University of Manchester, Manchester.
The visualizations for "The University of Manchester - UK funding (£579,056): Understanding and predicting aggregation in biopharmaceuticals"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
